|
3结语
由于ARMD的致病因素及其病理生理机制以及该疾病的发生和发展过程尚无完全明了,所以在ARMD的治疗方面仍然没有出现一些有效的措施,现今医学界对新生血管型年龄相关性黄斑变性的治疗已经进行了大量的观察研究，以强有力的数据资料说明：激光光凝仅适用于少部分患者,而且治疗效果不尽人意；使用维替洛芬的光动力疗法，经瞳孔热疗等短期疗效较好，但如何减少治疗后CNV复发和残留,还要大样本长期随访；而像黄斑下手术之类的手术治疗其效果还需要大量的临床资料来进行观察，同时减少手术所带来的并发症也是需要攻克的一个难关；放射治疗的方法和技术还需要进一步完善；近年来不断涌现出的血管内皮生长因子抑制剂，皮质类固醇药物，维生素和矿物质元素尤其是锌等这一类老药新用，给人们带来了新的希望，然而将其应用于ARMD的治疗方面还需要更进一步的观察；国内也有报道将抗氧化类物质例如银杏提取物等应用于ARMD治疗，国外也有开展，但都因为观察样本量较小而无明显的说服力。期望在不久的将来能够探讨出一个有效的针对于ARMD的综合治疗方案,并在早期治疗方面有所突破。对于老年性眼病的防治工作具有重要意义。
【参考文献】
1 Bai ZL, Ren BC, Yang JG, He Y, Chen L, Sun NX. Epidemiological investigation on agerelated macular degeneration in rural area of Shaanxi Province,China. Int J Ophthalmol (Guoji Yanke Zazhi), 2005;5(6):11141121
2邹海东,张皙,许迅,汪枫桦,张世杰.上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查.中华眼科杂志,2005;41(1):1519
3 Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res,2007;26:137
4 王宜强,董晓光. 年龄相关性黄斑变性的流行病学和病因学研究进展.中华眼科杂志,2005;41(4):377381
5 Nilsson SE. From basic to clinical research: a journey with the retina, the retinal pigment epithelium, the cornea, agerelated macular degeneration and hereditary degenerations, as seen in the rear view mirror. Acta Ophthalmol Scand,2006;84:452465
6 Potter MJ, Szabo SM. Oneyear outcomes after photodynamic therapy in patients with agerelated macular degeneration with poor baseline visual acuity. Graefes Arch Clin Exp Ophthalmol,2006;244(8):10261028
7金陈进,周少博,胡卫群,葛坚,姜茹章,陈凌燕.光动力疗法对血管内皮细胞和视网膜色素上皮细胞的影.中山大学学报,2005;26(2):207210
8 Gelisken F, Inhoffen W, KarimZoda K, Grisanti S, Partsch M, Voelker M, BartzSchmidt KU. Subfoveal hemorrhage after verteporfin photodynamic therapy in treatment of choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol,2005;243:198203
9 Chaudhry NA, Lavaque AJ, Tom DE, Liggett PE. Large submacular hemorrhage following PDT with verteporfin in patients with occult CNVM secondary to agerelated macular degeneration. Ophthalmic Surg Laser Imag,2007;38:6468
10 Tatar O, Aeam A, Shinoda K, Stalmans P, Eckardt C, Luke M, BartzSchmidt KU, Grisanti S. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol,2006;142:95104
11 Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol,2006;142:660668
12 Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med,2004;351:28052816
13 Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N. Maximum tolerated dose of a humanized antivascular endothelial growth factor antibody fragment for treating neovascular agerelated macular degeneration. Ophthalmology,2005;112:10481053
14 Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration: twelveweek results of an uncontrolled openlabel clinical study. Ophthalmology,2005;112:10351047
15 Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maquire AM, Bennett J, Tolentino MJ. Small interfering RNA(siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis,2003;9:210216
16 Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer,2004;4:S81S85
17 Maier P, Unsoeld AS, Junker B, Martin G, Drevs J, Hansen LL, Aqostini HT. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischaemiainduced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol,2005;243:593600
18 Peter K. Kaiser, MD. Antivascular endothelial growth factor agentsand their development: therapeuticImplications in ocular diseases. Am J Ophthalmol,2006;142:660-668 上一页 [1] [2] |
